Sep 10, 2021 / 03:35PM GMT
Navann Ty - Citigroup Inc., Research Division - Director
Hi. Good morning, everyone. This is Navann Ty. I cover spec pharma at Citi, including Viatris. So Viatris is the combination of Mylan and Pfizer spin-off Upjohn business. And today, I have the pleasure of having with me Michael Goettler, who's the CEO of Viatris; Rajiv Malik, the President; and Bill Szablewski, the Head of Capital Markets.
So before I start the Q&A, I'll just hand over to Bill for forward-looking statement.
William Szablewski - Viatris Inc. - Head of Capital Markets
Yes. Thank you, Navann, and good morning, everybody. During today's discussion, we may make forward-looking statements on a number of matters. These forward-looking statements are subject to risks and uncertainty that could cause future results or events to differ materially from today's projections and discussion. Please refer to our SEC filings for a fuller explanation of those risks and uncertainties and the limits applicable to the forward-looking statements. Also, during today's discussion, we will not be
Viatris Inc at Citi BioPharma Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot